Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study

INTRODUCTION: This randomized, double-blind, placebo-controlled, 90-week study assessed safety, tolerability, and immunogenicity of CAD106 with/without adjuvant in patients with mild Alzheimer's disease. METHODS: One hundred twenty-one patients received up to seven intramuscular injections of C...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandenberghe, Rik, Riviere, Marie-Emmanuelle, Caputo, Angelika, Sovago, Judit, Maguire, R. Paul, Farlow, Martin, Marotta, Giovanni, Sanchez-Valle, Raquel, Scheltens, Philip, Ryan, J. Michael, Graf, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651373/
https://www.ncbi.nlm.nih.gov/pubmed/29067316
http://dx.doi.org/10.1016/j.trci.2016.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651373/
https://www.ncbi.nlm.nih.gov/pubmed/29067316
http://dx.doi.org/10.1016/j.trci.2016.12.003

Ejemplares similares